3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Breast Neoplasms
479
Carcinoma, Non-Small-Cell Lung
436
Prostatic Neoplasms
277
Lung Neoplasms
169
Stomach Neoplasms
138
Neoplasms
112
Squamous Cell Carcinoma of Head and Neck
109
Head and Neck Neoplasms
97
Neoplasm Metastasis
93
Esophageal Neoplasms
70
Ovarian Neoplasms
56
Pancreatic Neoplasms
41
Sarcoma
39
Urinary Bladder Neoplasms
38
Nasopharyngeal Carcinoma
32
Carcinoma, Squamous Cell
30
Triple Negative Breast Neoplasms
28
Carcinoma, Ovarian Epithelial
28
Adenocarcinoma of Lung
27
Adenocarcinoma
27
Esophageal Squamous Cell Carcinoma
26
Parkinson Disease 4, Autosomal Dominant Lewy Body
23
Carcinoma, Transitional Cell
23
Adenocarcinoma Of Esophagus
23
Breast Neoplasms, Male
22
Recurrence
21
Unspecified Adult Solid Tumor, Protocol Specific
20
Inflammatory Breast Neoplasms
20
Fallopian Tube Neoplasms
20
Melanoma
18
Interventions
Cyclophosphamide
9
Pemetrexed
6
pembrolizumab
5
fludarabine
5
Gemcitabine
5
Cisplatin
5
Carboplatin
5
ponatinib
4
atezolizumab
4
Rituximab
4
Dexamethasone
4
Bevacizumab
4
130-nm albumin-bound paclitaxel
4
Sunitinib
3
Melphalan
3
Doxorubicin
3
Bortezomib
3
tetulomab tetraxetan lu-177
2
pralsetinib
2
pomalidomide
2
osimertinib
2
napabucasin
2
isatuximab
2
fludarabine phosphate
2
ficlatuzumab
2
entrectinib
2
entinostat
2
durvalumab
2
cobimetinib
2
capmatinib
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Neoplasms by Histologic Type
×
Docetaxel
×
Clear all
NCT06463665
2026-06-04
VIRO-25
Genelux Corporation
Phase 2
Recruiting
142 enrolled